1. Doubling rituximab in high‐risk patients with aggressive B‐cell lymphoma ‐results of the DENSE‐R‐MegaCHOEP trial. (5th December 2018) Authors: Friedrichs, Birte; Nickelsen, Maike; Ziepert, Marita; Altmann, Bettina; Haenel, Mathias; Viardot, Andreas; Schmidt, Christian; Ruebe, Christian; Loeffler, Markus; Pfreundschuh, Michael; Rosenwald, Andreas; Glass, Bertram; Lenz, Georg; Schmitz, Norbert Journal: British journal of haematology Issue: Volume 184:Number 5(2019) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Issue 10216 (21st December 2019) Authors: Poeschel, Viola; Held, Gerhard; Ziepert, Marita; Witzens-Harig, Mathias; Holte, Harald; Thurner, Lorenz; Borchmann, Peter; Viardot, Andreas; Soekler, Martin; Keller, Ulrich; Schmidt, Christian; Truemper, Lorenz; Mahlberg, Rolf; Marks, Reinhard; Hoeffkes, Heinz-Gert; Metzner, Bernd; Dierlamm, Judi... Journal: Lancet Issue: Volume 394:Issue 10216(2019) Page Start: 2271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Issue 4 (April 2021) Authors: Frontzek, Fabian; Ziepert, Marita; Nickelsen, Maike; Altmann, Bettina; Glass, Bertram; Haenel, Mathias; Truemper, Lorenz; Held, Gerhard; Bentz, Martin; Borchmann, Peter; Dreyling, Martin; Viardot, Andreas; Kroschinsky, Frank P; Metzner, Bernd; Staiger, Annette M; Horn, Heike; Ott, German; Rosenwa... Journal: Lancet Issue: Volume 8:Issue 4(2021) Page Start: e267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗